Evaluation of the ID NOW among symptomatic individuals during the Omicron wave

William Stokes; Allison A. Venner; Emily Buss; Graham Tipples; Byron M. Berenger

doi:10.1099/jmm.0.001669

Volume 72, Issue 2

Research Article

Open Access

Evaluation of the ID NOW among symptomatic individuals during the Omicron wave

William Stokes^1,2,3, Allison A. Venner^1,4, Emily Buss¹, Graham Tipples^1,2,5 and Byron M. Berenger^1,4
View Affiliations Hide Affiliations

Affiliations: ¹ Alberta Precision Laboratories, Calgary, Alberta, Canada ² Department of Pathology and Laboratory Medicine, University of Alberta, Edmonton, Alberta, Canada ³ Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada ⁴ Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada ⁵ Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada
*Correspondence: William Stokes, [email protected]
Published: 27 February 2023 https://doi.org/10.1099/jmm.0.001669

Abstract

Introduction. Starting in December, 2020, the ID NOW was implemented throughout the province of Alberta, Canada (population 4.4 million) in various settings.

Gap statement. ID NOW’s test performance with SARS-CoV-2 Omicron variant BA.1 is unknown.

Aim. To assess the ID NOW performance among symptomatic individuals during the BA.1 Omicron wave and compare it to previous SARS-CoV-2 variant waves.

Methodology. The ID NOW was assessed in two locations among symptomatic individuals: rural hospitals and community assessment centres (AC) during the period 5–18 January 2022. Starting 5 January, Omicron represented >95 % of variants detected in our population. For every individual tested, two swabs were collected: one for ID NOW testing and the other for either reverse-transcriptase polymerase chain reaction (RT-PCR) confirmation of negative ID NOW results or for variant testing of positive ID NOW results.

Results. A total of 3041 paired samples were analysed (1139 RT-PCR positive). From this, 1873 samples were from 42 COVID-19 AC and 1168 from 69 rural hospitals. ID NOW sensitivity for symptomatic individuals presenting to community AC and rural hospitals was 96.0 % [95 % confidence interval (CI) 94.5–97.3 %, n=830 RT-PCR positive], and 91.6 % (95 % CI 87.9–94.4 %, n=309 RT-PCR positive), respectively. SARS-CoV-2 positivity rate was very high for both populations (44.3 % at AC, 26.5 % in hospital).

Conclusions. Sensitivity of ID NOW SARS-CoV-2, compared to RT-PCR, is very high during the BA.1 Omicron wave, and is significantly higher when compared to previous SARS-CoV-2 variant waves.

Received: 02/09/2022
Accepted: 05/02/2023
Published Online: 27/02/2023

Keyword(s): COVID-19 , ID NOW , POCT , rapid diagnostics , SARS-CoV-2 and symptomatic

This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001669

2023-02-27

2024-05-01

Full text loading...

/deliver/fulltext/jmm/72/2/jmm001669.html?itemId=/content/journal/jmm/10.1099/jmm.0.001669&mimeType=html&fmt=ahah

References

United States Food and Drug Administration ID NOW COVID-19 – instructions for use; 2020 https://www.fda.gov/media/136525/download accessed 10 February 2022
Stokes W, Venner AA, Buss E, Tipples G, Berenger BM. Prospective population-level validation of the Abbott ID NOW severe acute respiratory syndrome coronavirus 2 device implemented in multiple settings for testing asymptomatic and symptomatic individuals. Clin Microbiol Infect 2023; 29:247–252 [View Article]
[Google Scholar]
Abbott Evaluating Omicron and other COVID variants to ensure test effectiveness; 2021 https://www.abbott.com/corpnewsroom/diagnostics-testing/monitoring-covid-variants-to-ensure-test-effectiveness.html accessed 27 February 2022
Government of Alberta COVID-19 Alberta statistics; 2022 https://www.alberta.ca/stats/covid-19-alberta-statistics.htm accessed 27 February 2022
Zhao H, Lu L, Peng Z, Chen L-L, Meng X et al. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. Emerg Microbes Infect 2022; 11:277–283 [View Article] [PubMed]
[Google Scholar]
Pabbaraju Development and validation of reverse transcriptase-PCR assays for the testing of SARS-cov-2. JAMMI 2020 [View Article]
[Google Scholar]
Zelyas N, Pabbaraju K, Croxen MA, Lynch T, Buss E et al. Precision response to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays and genome sequencing for rapid variant detection and surveillance. Microbiol Spectr 2021; 9:e0031521 [View Article]
[Google Scholar]
Stokes W, Berenger BM, Singh T, Adeghe I, Schneider A et al. Acceptable performance of the Abbott ID NOW among symptomatic individuals with confirmed COVID-19. J Med Microbiol 2021; 70:34309503 [View Article] [PubMed]
[Google Scholar]
Stokes W, Kanji JN, Hu J, Zelyas N, Berenger BM. Wide variation in threshold cycle values clouds the interpretation of SARS-CoV-2 infectiousness. Clin Chem 2021; 68:253–255 [View Article]
[Google Scholar]
Peacock WF, Soto-Ruiz KM, House SL, Cannon CM, Headden G et al. Utility of COVID-19 antigen testing in the emergency department. J Am Coll Emerg Physicians Open 2022; 3:e12605 [View Article]
[Google Scholar]
Hay JA, Kissler SM, Fauver JR et al. Viral dynamics and duration of PCR positivity of the SARS-cov-2 omicron variant. medRxiv 2022 [View Article]
[Google Scholar]
Puhach O, Adea K, Hulo N, Sattonnet P, Genecand C et al. Infectious viral load in unvaccinated and vaccinated patients infected with SARS-CoV-2 WT, Delta and Omicron. medRxiv 2022 [View Article]
[Google Scholar]
Marais G, Hsiao N, Iranzadeh A, Doolabh D, Enoch A et al. Saliva swabs are the preferred sample for Omicron detection. medRxiv 2021 [View Article]
[Google Scholar]
Adamson B, Sikka R, Wyllie AL, Premsrirut P. Discordant SARS-CoV-2 PCR and rapid antigen test results when infectious: A December 2021 occupational case series. medRxiv 2022 [View Article]
[Google Scholar]

http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001669

Evaluation of the ID NOW among symptomatic individuals during the Omicron wave

J. Med. Microbiol. 72, 001669 (2023); https://doi.org/10.1099/jmm.0.001669

/content/journal/jmm/10.1099/jmm.0.001669

Data & Media loading...

Volume 72, Issue 2

Research Article

Open Access

Evaluation of the ID NOW among symptomatic individuals during the Omicron wave

Abstract

Most read this month

Most cited Most Cited RSS feed

Healthcare-associated infections, medical devices and biofilms: risk, tolerance and control

Emerging tick-borne pathogens of public health importance: a mini-review

Mechanisms of ciprofloxacin resistance in Pseudomonas aeruginosa: new approaches to an old problem

Evaluation of metal-based antimicrobial compounds for the treatment of bacterial pathogens

Pseudomonas aeruginosa – a phenomenon of bacterial resistance

The role of Akkermansia muciniphila in obesity, diabetes and atherosclerosis

Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung

Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children

The Microbial Ecology of the Large Bowel of Breastfed and Formula-fed Infants During the First Year of Life

Imbalance in the composition of the duodenal microbiota of children with coeliac disease